Abstract 【Objective】To investigate the expression and clinical significance of the receptor for advanced glycation end products (RAGE) and lysyl oxidase-like protein 2 (LOXL2) in renal cell carcinoma tissues.【Methods】Clinical data were collected from 152 patients with renal cell carcinoma who were scheduled for surgical treatment. The relationship between the expression of RAGE and LOXL2 in cancer tissues and the clinicopathological characteristics of the patients was analyzed. Patients were divided into a death group and a survival group based on whether they died within 5 years postoperatively. Clinical data between the two groups were compared, and factors influencing death within 5 years postoperatively were analyzed, as well as differences in survival curves between RAGE and LOXL2 positive and negative patients.【Results】The positive rates of RAGE and LOXL2 in renal cell carcinoma tissues were higher than those in adjacent tissues (P<0.05). The expression of RAGE and LOXL2 was related to tumor differentiation, tumor stage, and lymph node metastasis (P<0.05), but not to age, gender, tumor diameter, or renal capsule invasion (P>0.05). The proportion of age, lymph node metastasis, LOXL2 positivity, and RAGE positivity in the death group was higher than that in the survival group (P<0.05). Lymph node metastasis, RAGE positivity, and LOXL2 positivity were influencing factors for death within 5 years after surgery (P<0.05).【Conclusion】The positive rates of RAGE and LOXL2 in renal cell carcinoma tissues are high and they are related to tumor differentiation, tumor stage, and lymph node metastasis. RAGE and LOXL2 are positively correlated, and their detections can help assess patient prognosis.
SONG Zhifeng. Expression and Clinical Significance of RAGE and LOXL2 Proteins in Renal Cell Carcinoma[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(9): 1301-1304.
[1] BRAUN D A, BAKOUNY Z, HIRSCH L, et al. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma[J].Nat Rev Clin Oncol,2021,18(4):199-214.
[2] BEDKE J, ALBIGES L, CAPITANIO U, et al. Updated european association of urology guidelines on renal cell carcinoma:nivolumab plus cabozantinib joins immune Checkpoint inhibition combination therapies for treatment-naive metastatic clear-cell renal cell carcinoma[J].Eur Urol,2021,79(3):339-342.
[3] HU Z J, FANG W M, LIU Y, et al. Acute glucose fluctuation promotes RAGE expression via reactive oxygen speciesmediated NFkappaB activation in rat podocytes[J].Mol Med Rep,2021,23(5):330.
[4] SALVADOR F, MARTIN A, LOPEZ-MENENDEZ C, et al.Lysyl oxidase-like protein LOXL2 promotes lung metastasis of breast cancer[J].Cancer Res,2017,77(21):5846-5859.
[5] 牛海涛,王一,陈业刚,等. 2005年欧洲泌尿外科会议肾细胞癌诊断治疗指南[J].现代泌尿外科杂志,2006,11(2):121.
[6] GAMBICHLER T, MAHJURIAN-NAMARI M, REININGHAUS L, et al. Lysyl oxidase-like-2 mutations and reduced mRNA and protein expression in mid-dermal elastolysis[J].Clin Exp Dermatol,2019,44(1):47-51.
[7] PETEJOVA N, MARTINEK A. Renal cell carcinoma:Review of etiology, pathophysiology and risk factors[J].Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2016,160(2):183-194.
[8] MAKHOV P, JOSHI S, GHATALIA P, et al. Resistance to systemic therapies in clear cell renal cell carcinoma:mechanisms and management strategies[J].Mol Cancer Ther,2018,17(7):1355-1364.
[9] HUANG C Y, CHIANG S F, CHEN W T, et al. HMGB1 promotes ERK-mediated mitochondrial drp1 phosphorylation for chemoresistance through RAGE in colorectal cancer[J].Cell Death Dis,2018,9(10):1004.
[10] 马妮萨. 血清PTX3、肺癌组织中LOXL2蛋白表达与NSCLC患者预后的关系[J].实验与检验医学,2020,38(1):187-189.
[11] PALANISSAMI G, PAULS. RAGE and its ligands:molecular interplay between glycation, inflammation, and hallmarks of cancer-a review[J].Horm Cancer,2018,9(5):295-325.
[12] 胡健培,伍春羽,刘朝东. 赖氨酰氧化酶样蛋白2在肾细胞癌中的表达及其临床意义[J].基因组学与应用生物学,2019,38(3):1292-1297.
[13] 孙祥生,王雪松,吴冰冰. 肾细胞癌组织中HMGB1、RAGE表达变化及意义[J].山东医药,2020,60(4):53-56.
[1]
. [J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(9): 1442-1444.
2024, Vol. 41 
